How This Miracle Drug Disappeared Over Night

In 1996, Abbott Laboratories introduced ritonavir, a groundbreaking HIV protease inhibitor that transformed a terminal diagnosis into a manageable condition. By 1998, 75,000 patients were taking up to 20 capsules daily. After 240 consecutive successful production batches, quality control analysts noticed capsules were failing dissolution tests — they weren't dissolving fast enough to be properly absorbed. The capsules were turning white and cloudy, and microscopy revealed they were filled with millions of tiny needle-like crystals no one had ever seen before. Critically, even freshly synthesized ritonavir in the lab came out cloudy, and within weeks every batch from both the Chicago factory and an emergency backup factory in Italy had failed.

To explain the science behind this crisis, the video reaches back 170 years to a heated dispute between chemists Justus von Liebig and Friedrich Wöhler. Both had independently synthesized compounds with identical atomic compositions — one silver, one carbon, one nitrogen, one oxygen — yet their compounds behaved completely differently: Wöhler's was a stable powder (silver cyanate) while Liebig's was explosively sensitive (silver fulminate). After years of public argument, they met in Frankfurt and confirmed they were both correct. This led to the discovery of isomers — the principle that not just the atoms in a molecule, but their arrangement and bonding structure, determines how a substance behaves.

The video then introduces the concept of polymorphism through an extended chocolate-tempering demonstration with chef Chris Young. Chocolate has six polymorphic crystal forms of its cocoa butter fat. The desirable Form V is shiny, snappy, and melts at 34°C, while Form IV is dull, soft, and melts at 27°C. Through careful temperature management — melting, cooling to nucleate mixed crystals, then selectively reheating to eliminate unwanted forms — chocolatiers can consistently produce Form V. This illustrates how the same molecules stacked in different crystal arrangements produce dramatically different physical properties.

Returning to ritonavir, spectroscopic analysis confirmed that the white crystals were still ritonavir chemically, but the bonds were subtly different — it was a new polymorph, Form II, which was significantly more stable and therefore far less soluble than Form I. Unlike chocolate, where polymorphs can be interconverted through heating and cooling, the energy landscape for ritonavir made Form II essentially a thermodynamic trap — once formed, it was nearly impossible to revert to Form I.

The mechanism of spread is explained through the historical phenomenon of 'tin pest,' where tin metal undergoes a phase transition below 13°C from silvery beta-tin to crumbly gray alpha-tin. Once a small seed of the new form appears, it acts as a nucleation site that dramatically lowers the energy barrier for the transition, causing it to spread like an infection. The same mechanism explains the ritonavir disaster: once a seed crystal of Form II appeared — possibly from a production accident or random chance — it lowered the activation energy for other ritonavir molecules to adopt Form II. Seed crystals became airborne, contaminated clothing, spread throughout the production line, and when the Chicago team visited Italy, they unwittingly seeded that facility too.

Abbott held a press conference after five months of investigation, framing the event as an unpredictable natural phenomenon akin to a hurricane. Scientific experts interviewed in the video note that over half of all known compounds are polymorphic, and the number of known polymorphs for any compound increases with research investment. One researcher admits to accidentally discovering a second polymorph of aspirin, a drug that had been manufactured industrially for over 130 years. Today, at least five polymorphs of ritonavir are known. Pharmaceutical companies now spend hundreds of thousands to millions of dollars screening for polymorphs before and during drug production. Unable to recover Form I, Abbott ultimately abandoned the capsule formulation and reverted to an older, less patient-friendly liquid formulation. The case became a regulatory and scientific turning point for polymorph research in the pharmaceutical industry.